INTRODUCTION AND OBJECTIVES: WST11-VTP creates a strong antitumor immune reaction by exposing tumor antigens and trigging some systemic immune response. We postulated that the combination of VTP ablation with check point immune modulators OX-40 and PD-1 could improve local tumor control and survival in a murine urothelial cancer model. METHODS: 65 Black6 immunocompetent mice were Subcutaneous injected with Luciferase MB-49 cells in the right flank. After 14 days the tumors were measured and image performed. 8 groups were created with similar tumors dimension: controls (5), PD1 (5), OX40 (5), PD1þOX40 (10), VTP (10), VTPþPD1 (10), VTPþOX40 (10), VTPþPD1þOX40 (10). VTP was performed on day 15 and the antibodies on the day after following this schedule: single dose of OX40 and 6 doses of PD1 (one every 3 days). IVIS Spectrum images and tumor measurements were done once week until 90 days. The experiment was repeated twice. Immunohistochemistry and Flow cytometry of the tumor were done in 2 different endpoints for lymphocytes expression: 3 days and 7 days after VTP procedure. Statistical analysis was done using the GraphPadâ Prism 7 software RESULTS: After 90 days, the survival rate in the VTPs groups was 12.5%, 22.2%, 33% and 66% for VTP þ OX40, VTP þ PD1, VTP and VTPþPD1þOX40 (VPO) respectively (p<0.001). One mouse (10%) from OX40þPD1 combination survived whereas all mice from the others group without VTP died before 60 days (no statistical difference compared to control group). Only VPO group and OX40þPD1 group did not present lung metastasis in IVIS image during the study (p<0.001). Immunohistochemistry (IHC) showed statistical difference comparing CD4 and CD8 expression in VPO and OX40þPD1 with the others group (p<0.001), especially on day 7 after VTP. Similar results were demonstrated by flow cytometry on day 7: VPO increased fourfold in CD4, six fold in CD8 (Graph 1) and 15 times more in CD4þKi67 expression compare to VTP alone (p<0.001).
CONCLUSIONS: Ox-40 þ PD-1 immunotherapy in combination with VTP improves local tumor control and survival in MB-49 cell line model. The 2 different pathways combination seems rationale and encouraging approach in VTP treatment of urothelial cancer
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INTRODUCTION AND OBJECTIVES: Intravesical Bacillus
Calmette-Gu erin (BCG) immunotherapy has been used to treat nonmuscle invasive bladder cancer (BC) for 40 years but its underlying mechanism remains largely unknown. It is known that BCG adheres to integrin ?5?1integrins in the urothelial lining, which promotes its internalization through macropinocytosis and triggers an immune response cascade. Extracellular vesicles (EVs), small membrane-bound vesicles, act as immune modulators by transferring molecular cargos to recipient cells. We hypothesize that BCG internalization by BC cells increases their immune active EV release which could play key roles in mediating BCG-induced anti-tumor host immune responses, so the patient derived EVs may serve as predictive biomarkers that can differentiate BCG responders from non-responders.
METHODS: BC cell lines, human T24, 674V, HT1197, HT1376, J82, RT4, TCC-SUP, UMUC-3, 5637, and murine MB49, and immortalized bladder SV-HUC cells were treated with 1-4x106 CFU/ml live BCG. After 4-72 hours, BCG internalization was assessed by PCR analysis. In addition, secreted EVs were isolated by serial ultracentrifugation and analyzed by Nanoparticle Tracking Analysis. Cell lysate, total RNA and EVs were collected for immuno-molecular profiling by quantitative PCR and Western blotting analyses. The differences in BCG internalization capacity, alterations in EV secretion, gene and protein expression, and molecules from BC-derived EVs in response to BCG were compared among all cell lines.
RESULTS: In response to BCG treatment, J82, RT4, TCC-SUP, HT1376 BC cells and SV-HUC cells showed low BCG internalization levels and no changes in their EV secretion rates. Their immunomolecule expressions at cellular and EV levels also were not significantly altered after BCG treatment. In contrast, T24, 674V, HT1197, UMUC-3, 5637 and MB49 BC cell lines showed evident BCG internalization and their EV secretion rates were significantly increased after BCG treatment. In addition, the expression of the key molecules in modulating immune response, such as MHC and co-stimulatory molecules at gene and protein levels, were significantly upregulated as a result of BCG treatment. Critically, we found that only BC cells that internalize evident amounts of BCG released immune molecules-containing EVs in response to BCG. CONCLUSIONS: We conclude that BCG treatment resulted in increased EV release from BC cells with evident BCG internalization levels. In addition, BCG induced expression of key immuno-modulatory molecules in those BC cells and within their EVs. However, this effect was not seen in cells with low BCG internalization capacity. All these results together suggest that the increased EV release by some BC cells after BCG treatment seems to rely on their BCG internalization capacity. Therefore, changes in immunologically active EVs detected in patients' urine during BCG immunotherapy can be further explored as predictive biomarkers.
